Premium
Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti‐VEGF in large preterm babies
Author(s) -
Park Sang Woo,
Jung Hyun Ho,
Heo Hwan
Publication year - 2014
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/aos.12461
Subject(s) - medicine , retinopathy of prematurity , respiratory distress , fundus (uterus) , mechanical ventilation , gestational age , intraventricular hemorrhage , ophthalmology , ductus arteriosus , anesthesia , surgery , pregnancy , genetics , biology
Case 1 A premature baby boy born at 30 weeks gestation weighing 1600 g at birth was transferred to our institution for treatment of retinopathy of prematurity (ROP) at 32 weeks premenstrual age (PMA). The patient had respiratory distress syndrome immediately after birth requiring mechanical ventilation and received one dose of surfactant in the secondary hospital. He did not have patent ductus arteriosus (PDA), sepsis, intraventricular haemorrhage (IVH) and a history of blood transfusion. Initial examination disclosed bilateral aggressive posterior ROP (AP-ROP) in zone 1. At 32 weeks PMA, intravitreal ranibizumab (0.3 mg) was injected bilaterally. Fundus photographs and fluorescein angiography (FA) were taken using RetCam (Clarity Medical Systems, Pleasanton, CA) at preand post-treatment every month for 5 months after treatment (Fig. 1). Two months after treatment (40 weeks PMA), FA showed reactivation of conventional ROP and we again administered intravitreal ranibizumab (0.3 mg) by bilateral injection. At 2 months after the second injection (48 weeks PMA), leakages from the peripheral ridge were not observed and vessel tortuosity had significantly decreased, but the far peripheral retina had not fully vascularized (Fig. 1E). Case 2